Marc Scheineson comments on the Food and Drug Administration’s expected approach to regulating cannabidiol and cannabinoids in 2021.
新聞
January 3, 2021
Law360 | Product Liability Regulation & Legislation to Watch in 2021
-
新聞 July 22, 2021Inside Health Policy | HHS Adviser Called for FDA to Be More Aggressive in Cannabis SpaceMarc Scheineson is quoted on the U.S. Food and Drug Administration’s cannabidiol policies and safety regulations.
-
新聞 December 4, 2019Inside Health Policy, FDA Week | Expert: FDA Should Require CBD Companies to Register, List ProductsMarc Scheineson is quoted on how the U.S. Food & Drug Administration can exercise its authority by requiring companies to register and list their cannabidiol products.
-
新聞 August 6, 2019Inside Health Policy | Gottlieb, Experts: Industry Can Use NDIs, Petitions to Show CBD SafetyMarc Scheineson is quoted on how the U.S. Food and Drug Administration can use the “generally recognized as safe” affirmation process to prove the safety of cannabidiol products.
-
新聞 April 30, 2019The Hill | Booming Cannabis Market Puts Pressure on FDAMarc Scheineson comments on efforts by the U.S. Food & Drug Administration to regulate cannabidiol and hemp products.
-
新聞 April 3, 2019Associated Press | CBD is Getting Buzz, but Does It Work? And Is It Legal?Marc Scheineson is quoted on the U.S. Food and Drug Administration’s authority and resources for policing cannabidiol products.